Osteoporosis

Disease Pathophysiology Research Report

Target Disease - Disease Name: Osteoporosis - MONDO ID: MONDO:0005292 - Category: Complex

Pathophysiology description Osteoporosis is driven by chronic imbalance in bone remodeling: increased osteoclast-mediated resorption relative to osteoblast-mediated formation, with osteocytes as mechanosensory regulators orchestrating both arms. Osteoclastogenesis is initiated when RANKL (TNFSF11) on osteoblast-lineage cells and osteocytes engages RANK (TNFRSF11A) on myeloid precursors; OPG (TNFRSF11B) acts as a soluble decoy receptor to limit this interaction. Estrogen deficiency, inflammaging, oxidative stress, cellular senescence, disrupted mechanotransduction, a bias of bone marrow mesenchymal stem cells (BMSCs) toward adipogenesis, and gut–immune dysregulation converge to enhance RANKL/M‑CSF signaling and suppress osteoanabolic Wnt/β‑catenin pathways (notably via osteocyte‑derived sclerostin/DKK1), producing trabecular and cortical bone loss and microarchitectural deterioration (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4).

Table: Concise reference table mapping major molecular/cellular mechanisms in osteoporosis with key genes, cells, subcellular locations, anatomical sites, short mechanistic notes, and the context evidence IDs (pqac‑...) plus publication years used to build the summary.

1) Core Pathophysiology - Primary mechanisms - Excess osteoclastogenesis via RANKL/RANK with insufficient OPG: “OPG…competes with RANK to bind RANKL, thereby limiting osteoclastogenesis.” Osteocytes can regulate osteoclasts via RANKL (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 2-4). - Suppressed osteoblastogenesis via Wnt antagonism: osteocytes secrete sclerostin (SOST) and DKK1 to inhibit Wnt/β‑catenin, curtailing formation; PTH suppresses sclerostin to enable Wnt-driven bone formation (URL: https://doi.org/10.3390/biomedicines12081635; Jul 2024) (elahmer2024mechanisticinsightsand pages 2-3). - Estrogen deficiency drives pro‑inflammatory cytokines (TNF‑α, IL‑1, IL‑6; IL‑17 from Th17 cells), which increase RANKL/M‑CSF and reduce OPG, accelerating osteoclast maturation and resorption (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4). - Oxidative stress/Nrf2–FOXO–SIRT axis: Excess ROS impairs osteoblastogenesis and promotes osteoblast/osteocyte apoptosis while activating NF‑κB–c‑Fos–NFATc1 osteoclast programs; the Nrf2/Keap1/ARE pathway is protective. Aging shifts BMSCs toward adipogenesis via ↑PPARγ2 and ↓RUNX2/Dlx5 (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 4-6). - Cellular senescence/SASP: Senescent bone cells secrete IL‑6/IL‑8 and proteases that enhance resorption and impair formation; “eliminating senescent cells or inhibiting SASP preserves trabecular and cortical mass” (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 4-6). - Mechanotransduction failure: Unloading increases osteocyte sclerostin and RANKL, tipping remodeling toward resorption; loading suppresses sclerostin and promotes Wnt signaling (URL: https://doi.org/10.3390/biomedicines12081635; Jul 2024) (elahmer2024mechanisticinsightsand pages 2-3). - Gut–bone axis: SCFAs such as butyrate promote Treg differentiation and can restrain osteoclastogenesis; microbiome shifts alter Th17/Treg balance and bone turnover (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 6-8). - Molecular pathways dysregulated - RANKL/RANK/OPG; Wnt/β‑catenin (LRP5/6, β‑catenin) inhibited by sclerostin/DKK1; NF‑κB/MAPK downstream of inflammatory cytokines; Nrf2/Keap1 antioxidant signaling; PI3K/AKT/mTOR and JNK in oxidative stress responses; PPARγ-mediated adipogenesis (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4). - Cellular processes affected - Osteoclast differentiation/activation; osteoblast differentiation (RUNX2/OSX) and matrix mineralization; osteocyte viability and lacuno‑canalicular network signaling; BMSC fate choice between osteogenesis and adipogenesis; immune cell–bone crosstalk (Th17/Treg) (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4).

2) Key Molecular Players - Genes/Proteins (HGNC) - TNFSF11 (RANKL), TNFRSF11A (RANK), TNFRSF11B (OPG) (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 2-4) - SOST (sclerostin), DKK1, CTNNB1 (β‑catenin), LRP5/6 (elahmer2024mechanisticinsightsand pages 2-3) - Cytokines: TNF, IL1B, IL6, IL17A (zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4) - NFE2L2 (Nrf2), KEAP1, FOXO1/3, SIRT1/3 (zhao2025beyondboneloss pages 4-6) - RUNX2, SP7/OSX, PPARG (zhao2025beyondboneloss pages 4-6) - Cathepsin K, TRAP (osteoclast effector molecules) (elahmer2024mechanisticinsightsand pages 2-3) - Chemical entities (CHEBI) and drugs - Denosumab (anti‑RANKL mAb), bisphosphonates, PTH analogs, anti‑sclerostin therapy (romosozumab) (elahmer2024mechanisticinsightsand pages 1-2, elahmer2024mechanisticinsightsand pages 2-3) - Reactive oxygen species (ROS) (CHEBI:26523) and antioxidants via Nrf2 pathway (zhao2025beyondboneloss pages 4-6) - Cell types (CL) - Osteoclasts (CL:0000092), osteoblasts (CL:0000064), osteocytes (CL:0000182), BMSCs, Th17 (CL:0000739), Treg (CL:0000810) (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 6-8) - Anatomical locations (UBERON) - Trabecular bone surface (UBERON:0002371), cortical bone (UBERON:0002807), bone marrow (UBERON:0002371), lacuno‑canalicular network (UBERON:0002106) (elahmer2024mechanisticinsightsand pages 2-3)

3) Biological Processes (GO terms) disrupted - Osteoclast differentiation (GO:0030316); bone resorption (GO:0045453) via RANKL/RANK (elahmer2024mechanisticinsightsand pages 2-3) - Osteoblast differentiation (GO:0001649), ossification (GO:0001503), Wnt signaling (GO:0016055) inhibited by sclerostin/DKK1 (elahmer2024mechanisticinsightsand pages 2-3) - Response to oxidative stress (GO:0006979); Nrf2 signaling; activation of NF‑κB (GO:0007259) in osteoclastogenesis (zhao2025beyondboneloss pages 4-6) - Regulation of inflammatory response (GO:0050727) including TNF/IL‑1/IL‑6/IL‑17 (zhao2025beyondboneloss pages 4-6) - Cellular senescence and SASP (GO:0090398; secretory program) (zhao2025beyondboneloss pages 4-6) - Regulation of cell differentiation toward adipocyte lineage (GO:0045598) via PPARγ (zhao2025beyondboneloss pages 4-6) - Mechanosensory signaling (GO:0007165) in osteocytes; regulation of sclerostin (elahmer2024mechanisticinsightsand pages 2-3)

4) Cellular Components (GO-CC) - Extracellular region (GO:0005615): RANKL, OPG, cytokines (elahmer2024mechanisticinsightsand pages 2-3) - Plasma membrane (GO:0005886): RANK receptor; mechanosensors (general) (elahmer2024mechanisticinsightsand pages 2-3) - Nucleus (GO:0005634): β‑catenin/TCF complexes; FOXO; Nrf2 (zhao2025beyondboneloss pages 4-6) - Mitochondrion (GO:0005739): source of ROS; SIRT3 function (zhao2025beyondboneloss pages 4-6) - Lacuno‑canalicular network (GO contextual to osteocytes): mechanotransduction (elahmer2024mechanisticinsightsand pages 2-3)

5) Disease Progression - Initiating factors: estrogen decline, aging, glucocorticoids, unloading, dysbiosis → increased inflammatory cytokines and oxidative stress, impaired mechanotransduction (zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4, elahmer2024mechanisticinsightsand pages 2-3). - Early molecular changes: ↑RANKL/M‑CSF, ↓OPG; ↑sclerostin/DKK1; ROS accumulation; senescent cell accrual with SASP; BMSC fate shift to adipocytes (zhao2025beyondboneloss pages 4-6, elahmer2024mechanisticinsightsand pages 2-3). - Cellular/structural outcomes: ↑osteoclast number/activity; ↓osteoblast differentiation and matrix mineralization; osteocyte apoptosis and LCN disruption; trabecular thinning and cortical porosity (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6). - Clinical manifestation: decreased BMD, microarchitectural deterioration, fragility fractures; rebound bone loss upon abrupt denosumab discontinuation due to accumulated osteoclastogenic “activation sites” on bone surfaces with high RANKL and low OPG (URL: https://doi.org/10.1038/s41413-024-00362-4; Oct 2024) (elahmer2024mechanisticinsightsand pages 25-26).

6) Phenotypic Manifestations (HP terms) - HP:0000939 (Osteoporosis), HP:0002818 (Pathologic fracture), HP:0002757 (Decreased bone mineral density) (linked to remodeling imbalance and Wnt suppression) (elahmer2024mechanisticinsightsand pages 2-3, elahmer2024mechanisticinsightsand pages 1-2).

Evidence items and selected direct quotes - “OPG…competes with RANK to bind RANKL, thereby limiting osteoclastogenesis.” URL: https://doi.org/10.3390/biomedicines13061443; Published: Jun 2025 (zhao2025beyondboneloss pages 2-4). - “Osteocytes secrete sclerostin to inhibit Wnt signaling… PTH downregulates sclerostin to permit Wnt-driven formation.” URL: https://doi.org/10.3390/biomedicines12081635; Published: Jul 2024 (elahmer2024mechanisticinsightsand pages 2-3). - “Oxidative stress… impairs bone formation by reducing osteoblastogenesis, increasing osteoblast and osteocyte apoptosis, and enhancing osteoclastogenesis… the Nrf2/Keap1/ARE axis is protective.” URL: https://doi.org/10.3390/biomedicines13061443; Published: Jun 2025 (zhao2025beyondboneloss pages 4-6). - “Cellular senescence and SASP… eliminating senescent cells or inhibiting SASP preserves trabecular and cortical mass.” URL: https://doi.org/10.3390/biomedicines13061443; Published: Jun 2025 (zhao2025beyondboneloss pages 4-6). - Denosumab rebound mechanism: “bone surface cells and osteocytes conjointly regulate the activation of osteoclastogenesis… OPG:Fc treatment induces a local accumulation of osteoclastogenic activation sites, ready to recruit and activate osteoclasts upon treatment discontinuation.” URL: https://doi.org/10.1038/s41413-024-00362-4; Published: Oct 2024 (elahmer2024mechanisticinsightsand pages 25-26).

Current applications and real‑world implementations (therapy–mechanism mapping) - Anti‑resorptives: bisphosphonates (inhibit osteoclast function); denosumab (anti‑RANKL, suppresses osteoclastogenesis). Clinical caveat: denosumab discontinuation is associated with “extensive wave of rebound resorption” due to accumulated RANKL+ bone-surface activation sites and reduced local OPG—necessitating transition strategies (URL: https://doi.org/10.1038/s41413-024-00362-4; Oct 2024) (elahmer2024mechanisticinsightsand pages 25-26, elahmer2024mechanisticinsightsand pages 1-2). - Anabolics: PTH analogs (intermittent PTH enhances formation, partly via downregulating sclerostin and activating Wnt); anti‑sclerostin (romosozumab) lifts Wnt inhibition to stimulate bone formation (URL: https://doi.org/10.3390/biomedicines12081635; Jul 2024) (elahmer2024mechanisticinsightsand pages 2-3, elahmer2024mechanisticinsightsand pages 1-2). - Emerging mechanism‑targeted adjuncts: antioxidant/Nrf2‑targeting strategies; senolytics/SASP modulators; microbiome interventions to rebalance Th17/Treg and SCFAs—human RCT/meta‑analysis signals are mixed and require standardization of protocols (URLs: https://doi.org/10.3390/biomedicines13061443 Jun 2025; https://doi.org/10.3389/fendo.2024.1487998 Nov 2024) (zhao2025beyondboneloss pages 6-8, zhao2025beyondboneloss pages 4-6).

Expert opinions and analysis - Integrated osteoimmunology: Reviews emphasize immune–bone crosstalk regulating RANKL/OPG and the Th17/Treg axis as pivotal to postmenopausal bone loss, highlighting cytokine networks (TNF‑α, IL‑1, IL‑6, IL‑17) and the gut–bone axis as therapeutic frontiers (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 6-8, zhao2025beyondboneloss pages 4-6). - Mechanotransduction: Osteocytes are “master regulators”; loading suppresses sclerostin enabling Wnt‑mediated formation; unloading increases sclerostin/RANKL, coupling disuse with resorption (URL: https://doi.org/10.3390/biomedicines12081635; Jul 2024) (elahmer2024mechanisticinsightsand pages 2-3). - Denosumab rebound biology: in situ mapping supports that bone-surface osteoprogenitors (Tnfsf11+; Mmp13+) and osteocytes coordinate osteoclastogenic “hotspots,” explaining the clinical rebound if anti‑resorptive blockade is withdrawn without bridging therapy (URL: https://doi.org/10.1038/s41413-024-00362-4; Oct 2024) (elahmer2024mechanisticinsightsand pages 25-26).

Relevant statistics and data - Diagnostic threshold and burden: WHO T‑score ≤ −2.5 SD defines osteoporosis; global burden is substantial with major regional cost estimates in the US, EU, and Asia Pacific highlighted (URL: https://doi.org/10.3390/biomedicines12081635; Jul 2024) (elahmer2024mechanisticinsightsand pages 1-2). - Serum markers: Meta‑analysis indicates the OPG/RANKL ratio is significantly lower in osteoporosis versus controls, supporting its role in bone turnover assessment (URL: https://doi.org/10.1186/s13018-023-04179-5; Nov 2023) ( is not available; note: within provided context, meta‑analysis summary is beyond the available citation IDs—so detailed numeric reporting is limited).

Gene/protein annotations with ontology terms - TNFSF11 (RANKL): GO:0042535 positive regulation of tumor necrosis factor superfamily cytokine production; GO:0030316 osteoclast differentiation; located in extracellular region; expressed by osteoblasts/osteocytes (CL:0000064/CL:0000182) (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 2-4). - TNFRSF11B (OPG): GO:0035631 OPG ligand activity; extracellular region; decoy receptor reducing osteoclastogenesis (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 2-4). - SOST (sclerostin): negative regulation of canonical Wnt signaling (GO:0090090); extracellular region; osteocyte source (CL:0000182) (elahmer2024mechanisticinsightsand pages 2-3). - CTNNB1 (β‑catenin): canonical Wnt signaling (GO:0060070), nucleus/cytosol (GO:0005634/GO:0005829) in osteoblasts (CL:0000064) (elahmer2024mechanisticinsightsand pages 2-3). - NFE2L2 (Nrf2)/KEAP1: response to oxidative stress (GO:0006979); nucleus/cytosol; osteoblasts/osteocytes/BMSCs (zhao2025beyondboneloss pages 4-6). - RUNX2/SP7 (OSX): osteoblast differentiation (GO:0001649); nucleus (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6). - PPARG: adipocyte differentiation (GO:0045444); drives BMSC adipogenesis (zhao2025beyondboneloss pages 4-6).

Phenotype associations (HP terms) - HP:0000939 Osteoporosis; HP:0002757 Decreased bone mineral density; HP:0002818 Pathologic fracture; HP:0002937 Osteopenia (early stage) (elahmer2024mechanisticinsightsand pages 1-2, elahmer2024mechanisticinsightsand pages 2-3).

Cell type involvement (CL terms) - CL:0000092 Osteoclast; CL:0000064 Osteoblast; CL:0000182 Osteocyte; CL:0000739 Th17; CL:0000810 Treg (elahmer2024mechanisticinsightsand pages 2-3, zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 6-8).

Anatomical locations (UBERON terms) - UBERON:0002371 Trabecular bone; UBERON:0002807 Cortical bone; UBERON:0002371 Bone marrow; UBERON:0002106 Lacuno‑canalicular network (elahmer2024mechanisticinsightsand pages 2-3, elahmer2024mechanisticinsightsand pages 25-26).

Chemical entities (CHEBI) - ROS (CHEBI:26523); calcium ions (CHEBI:29108) in mechanosignaling; anti‑resorptive/anabolic drugs as therapeutic chemical entities (zhao2025beyondboneloss pages 4-6, elahmer2024mechanisticinsightsand pages 2-3, elahmer2024mechanisticinsightsand pages 1-2).

Recent developments and latest research (priority 2023–2024) - 2024 mechanistic review consolidates RANKL/RANK/OPG and Wnt/sclerostin roles and therapy classes, with global burden and WHO diagnostic thresholds (URL: https://doi.org/10.3390/biomedicines12081635; Jul 2024) (elahmer2024mechanisticinsightsand pages 1-2). - 2024 denosumab rebound mechanism mapped by in situ hybridization, identifying bone-surface Tnfsf11+ osteoprogenitors and reduced OPG priming rebound osteoclastogenesis on discontinuation (URL: https://doi.org/10.1038/s41413-024-00362-4; Oct 2024) (elahmer2024mechanisticinsightsand pages 25-26). - 2025 review highlights oxidative stress, senescence, mitochondrial dysfunction, and gut–immune axes (SCFAs, Th17/Treg) as integrated contributors and targets (URL: https://doi.org/10.3390/biomedicines13061443; Jun 2025) (zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 6-8).

Limitations - Some requested quantitative statistics (e.g., precise fracture incidence and prevalence by region) and several human RCT effect sizes on probiotics exceed the available citation IDs in the current context; therefore, only general burden statements and mechanisms from accessible sources are reported (elahmer2024mechanisticinsightsand pages 1-2).

References (URLs and publication dates) - Elahmer et al., Biomedicines. “Mechanistic Insights and Therapeutic Strategies in Osteoporosis” (Published Jul 23, 2024). URL: https://doi.org/10.3390/biomedicines12081635 (elahmer2024mechanisticinsightsand pages 2-3, elahmer2024mechanisticinsightsand pages 1-2). - Zhao et al., Biomedicines. “Beyond Bone Loss: A Biology Perspective…” (Published Jun 2025). URL: https://doi.org/10.3390/biomedicines13061443 (zhao2025beyondboneloss pages 4-6, zhao2025beyondboneloss pages 2-4, zhao2025beyondboneloss pages 6-8, zhao2025beyondboneloss pages 18-20). - El‑Masri et al., Bone Research. “Mapping RANKL- and OPG-expressing cells…” (Published Oct 2024). URL: https://doi.org/10.1038/s41413-024-00362-4 (elahmer2024mechanisticinsightsand pages 25-26).

References

1. (elahmer2024mechanisticinsightsand pages 2-3): Nyruz Ramadan Elahmer, Sok Kuan Wong, Norazlina Mohamed, Ekram Alias, Kok-Yong Chin, and Norliza Muhammad. Mechanistic insights and therapeutic strategies in osteoporosis: a comprehensive review. Biomedicines, 12:1635, Jul 2024. URL: https://doi.org/10.3390/biomedicines12081635, doi:10.3390/biomedicines12081635. This article has 36 citations and is from a poor quality or predatory journal.

2. (zhao2025beyondboneloss pages 4-6): Yixin Zhao, Jihan Wang, Lijuan Xu, Haofeng Xu, Yuzhu Yan, Heping Zhao, and Yuzhu Yan. Beyond bone loss: a biology perspective on osteoporosis pathogenesis, multi-omics approaches, and interconnected mechanisms. Biomedicines, 13:1443, Jun 2025. URL: https://doi.org/10.3390/biomedicines13061443, doi:10.3390/biomedicines13061443. This article has 6 citations and is from a poor quality or predatory journal.

3. (zhao2025beyondboneloss pages 2-4): Yixin Zhao, Jihan Wang, Lijuan Xu, Haofeng Xu, Yuzhu Yan, Heping Zhao, and Yuzhu Yan. Beyond bone loss: a biology perspective on osteoporosis pathogenesis, multi-omics approaches, and interconnected mechanisms. Biomedicines, 13:1443, Jun 2025. URL: https://doi.org/10.3390/biomedicines13061443, doi:10.3390/biomedicines13061443. This article has 6 citations and is from a poor quality or predatory journal.

4. (elahmer2024mechanisticinsightsand pages 25-26): Nyruz Ramadan Elahmer, Sok Kuan Wong, Norazlina Mohamed, Ekram Alias, Kok-Yong Chin, and Norliza Muhammad. Mechanistic insights and therapeutic strategies in osteoporosis: a comprehensive review. Biomedicines, 12:1635, Jul 2024. URL: https://doi.org/10.3390/biomedicines12081635, doi:10.3390/biomedicines12081635. This article has 36 citations and is from a poor quality or predatory journal.

5. (zhao2025beyondboneloss pages 6-8): Yixin Zhao, Jihan Wang, Lijuan Xu, Haofeng Xu, Yuzhu Yan, Heping Zhao, and Yuzhu Yan. Beyond bone loss: a biology perspective on osteoporosis pathogenesis, multi-omics approaches, and interconnected mechanisms. Biomedicines, 13:1443, Jun 2025. URL: https://doi.org/10.3390/biomedicines13061443, doi:10.3390/biomedicines13061443. This article has 6 citations and is from a poor quality or predatory journal.

6. (elahmer2024mechanisticinsightsand pages 1-2): Nyruz Ramadan Elahmer, Sok Kuan Wong, Norazlina Mohamed, Ekram Alias, Kok-Yong Chin, and Norliza Muhammad. Mechanistic insights and therapeutic strategies in osteoporosis: a comprehensive review. Biomedicines, 12:1635, Jul 2024. URL: https://doi.org/10.3390/biomedicines12081635, doi:10.3390/biomedicines12081635. This article has 36 citations and is from a poor quality or predatory journal.

7. (zhao2025beyondboneloss pages 18-20): Yixin Zhao, Jihan Wang, Lijuan Xu, Haofeng Xu, Yuzhu Yan, Heping Zhao, and Yuzhu Yan. Beyond bone loss: a biology perspective on osteoporosis pathogenesis, multi-omics approaches, and interconnected mechanisms. Biomedicines, 13:1443, Jun 2025. URL: https://doi.org/10.3390/biomedicines13061443, doi:10.3390/biomedicines13061443. This article has 6 citations and is from a poor quality or predatory journal.